Breaking
RAPS Euro Convergence: Top Regulatory Insights - Day 1European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1
🇺🇸 FDA

Lung Cancer

Page 1 • 1 item

Gain critical insights into global lung cancer drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.

Boehringer Ingelheim's Zongertinib Shows Promise for HER2-Mutant Lung Cancer in NEJM Study
NewsNon-small cell lung cancer (NSCLC)Apr 17, 2026

Boehringer Ingelheim's Zongertinib Shows Promise for HER2-Mutant Lung Cancer in NEJM Study

Boehringer Ingelheim's zongertinib demonstrates efficacy in HER2-mutant NSCLC patients, with Phase 1b Beamion LUNG-1 results published in NEJM following FDA approval.

James Chen, PharmD